NASDAQ:BWV

Onconetix (BWV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.18
$0.20
50-Day Range
$0.18
$0.18
52-Week Range
$0.18
$1.95
Volume
534,200 shs
Average Volume
795,235 shs
Market Capitalization
$3.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BWV stock logo

About Onconetix Stock (NASDAQ:BWV)

Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

BWV Stock News Headlines

BWV Blue Water Biotech, Inc.
The AI Stock that’s Disrupting Every Industry
Move over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…
Blue Water Biotech Acquires Proteomedix AG
Blue Water Biotech Inc.
See More Headlines
Receive BWV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BWV
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-13,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.63 per share

Miscellaneous

Free Float
15,017,000
Market Cap
$3.36 million
Optionable
Not Optionable
Beta
3.58
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. James R. Sapirstein M.B.A. (Age 62)
    R.Ph., Interim Executive Chairman
    Comp: $65.62k
  • Ms. Erin Henderson (Age 48)
    Chief Business Officer & Corporate Secretary
    Comp: $526.9k
  • Dr. Neil J. Campbell MA (Age 63)
    MBA, President, CEO & Director
  • Mr. Bruce Harmon (Age 65)
    Chief Financial Officer
  • Dr. Brian Price Ph.D.
    Head of Technology Strategy
  • Mr. Frank A. Jaeger M.A. (Age 52)
    M.B.A., Senior VP of Marketing & Business Development
  • Mr. Andrew D. Skibo Ph.D.
    Global Head of Biologics Operations
  • Mr. Theodore Scott Yoho
    Head of Business Development
  • Dr. Ali I. Fattom Ph.D.
    Head of Science & Discovery
  • Dr. Jay Newmark M.B.A.
    M.D., Chief Medical Officer

BWV Stock Analysis - Frequently Asked Questions

Should I buy or sell Onconetix stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconetix in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BWV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BWV, but not buy additional shares or sell existing shares.
View BWV analyst ratings
or view top-rated stocks.

When did Onconetix IPO?

Onconetix (BWV) raised $20 million in an IPO on Friday, February 18th 2022. The company issued 2,222,222 shares at a price of $9.00 per share.

This page (NASDAQ:BWV) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners